Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Boman

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Lakartidningen|July 16, 1999
[Cost-effectiveness analysis of cardiovascular disease prevention: a graded list as aid to the rational distribution of resources]L Lindholm, C G Hallgren, K Boman, et al.
Consciousness and Cognition|October 4, 2011
On the validity of remember-know judgments: evidence from think aloud protocolsDavid P McCabe, Lisa Geraci, Jeffrey K Boman, et al.
Health Policy (Amsterdam, Netherlands)|November 7, 2000
Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease?L Lindholm, C G Hallgren, K Boman, et al.
Stroke|January 8, 2000
Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first strokeL Johansson, J H Jansson, K Boman, et al.
Pacing and Clinical Electrophysiology : PACE|July 1, 1987
Cardiac stimulation threshold in familial amyloidosis with polyneuropathyJ H Jansson, P Eriksson, K Boman, et al.
Journal of Internal Medicine|January 1, 1991
Assessment of hypothalamic-pituitary function in patients with familial amyloidotic polyneuropathyB O Olofsson, K Grankvist, T Olsson, et al.
Journal of Internal Medicine|June 29, 2011
Von Willebrand factor predicts major bleeding and mortality during oral anticoagulant treatmentM Lind, K Boman, L Johansson, et al.
Journal of Internal Medicine|January 17, 2003
The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarctionJ B Nilsson, T K Nilsson, J H Jansson, et al.
Journal of Epidemiology and Community Health|July 9, 1999
Shifting the distribution of risk: results of a community intervention in a Swedish programme for the prevention of cardiovascular diseaseL Weinehall, G Westman, G Hellsten, et al.
Journal of Internal Medicine|October 22, 2005
Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery diseaseJ Oldgren, C Fellenius, K Boman, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Lakartidningen|July 16, 1999
[Cost-effectiveness analysis of cardiovascular disease prevention: a graded list as aid to the rational distribution of resources]L Lindholm, C G Hallgren, K Boman, et al.
Consciousness and Cognition|October 4, 2011
On the validity of remember-know judgments: evidence from think aloud protocolsDavid P McCabe, Lisa Geraci, Jeffrey K Boman, et al.
Health Policy (Amsterdam, Netherlands)|November 7, 2000
Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease?L Lindholm, C G Hallgren, K Boman, et al.
Stroke|January 8, 2000
Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first strokeL Johansson, J H Jansson, K Boman, et al.
Pacing and Clinical Electrophysiology : PACE|July 1, 1987
Cardiac stimulation threshold in familial amyloidosis with polyneuropathyJ H Jansson, P Eriksson, K Boman, et al.
Journal of Internal Medicine|January 1, 1991
Assessment of hypothalamic-pituitary function in patients with familial amyloidotic polyneuropathyB O Olofsson, K Grankvist, T Olsson, et al.
Journal of Internal Medicine|June 29, 2011
Von Willebrand factor predicts major bleeding and mortality during oral anticoagulant treatmentM Lind, K Boman, L Johansson, et al.
Journal of Internal Medicine|January 17, 2003
The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarctionJ B Nilsson, T K Nilsson, J H Jansson, et al.
Journal of Epidemiology and Community Health|July 9, 1999
Shifting the distribution of risk: results of a community intervention in a Swedish programme for the prevention of cardiovascular diseaseL Weinehall, G Westman, G Hellsten, et al.
Journal of Internal Medicine|October 22, 2005
Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery diseaseJ Oldgren, C Fellenius, K Boman, et al.
Pageof 11